Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Alzheimer's disease: an integrative bioinformatics and machine learning analysis reveals glutamine metabolism-associated gene biomarkers.
BMC Pharmacol Toxicol
January 2025
Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, 264100, PR China.
Background: Alzheimer's disease (AD), a hallmark of age-related cognitive decline, is defined by its unique neuropathology. Metabolic dysregulation, particularly involving glutamine (Gln) metabolism, has emerged as a critical but underexplored aspect of AD pathophysiology, representing a significant gap in our current understanding of the disease.
Methods: To investigate the involvement of GlnMgs in AD, we conducted a comprehensive bioinformatic analysis.
Background: Telehealth is gaining importance in improving healthcare access and outcomes, particularly in underserved regions. Despite its potential, healthcare providers in developing countries struggle to effectively utilize telehealth tools, highlighting the need for structured training. This study aims to develop and validate a specialized tool to assess the telehealth educational environment, addressing the unique challenges of integrating clinical, technological, and interpersonal skills in telehealth education.
View Article and Find Full Text PDFAssessment of healthcare workers' knowledge and availability of resources for sickle cell disease management in Bukavu, Democratic Republic of the Congo.
BMC Health Serv Res
January 2025
Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
Introduction: Sickle cell disease (SCD) is a global public health priority due to its high morbidity and mortality. In the Democratic Republic of the Congo (DRC), effective care for this disease depends on the availability of resources and the level of knowledge of healthcare workers (HCWs). However, in Bukavu, there is limited data available on these two crucial aspects, which are vital for enhancing the care of patients with SCD.
View Article and Find Full Text PDFDental and oral health assessments in the German National Cohort (NAKO).
BMC Oral Health
January 2025
Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Greifswald, Germany.
Background: Despite considerable improvements in oral health in recent decades, caries and periodontitis are still widespread, ranking among the most prevalent diseases worldwide and requiring future research. The German National Cohort (NAKO Gesundheitsstudie, NAKO) is a large-scaled, multidisciplinary, nationwide, multi-centre, population-based, prospective cohort study with oral examinations that aims to provide a resource to study risk factors for major diseases. The aim of the present article is to provide the methodological background, to report on the data quality, and to present initial results of the oral examinations.
View Article and Find Full Text PDFLipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.
Drugs Real World Outcomes
January 2025
Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center of the Charité, Berlin, Germany.
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.
Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!